Engflag

Amidate

Quick links to important sections

Amidate

Amidate_DA

Method of action: Anesthesia, Anesthetic, Anticonvulsant

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Amidate

What is Amidate? Defining the Anesthetic Entity

Property Description
Active ingredient Etomidate
Form Intravenous solution or lipid emulsion
Pharmacological class General Anesthetic, Hypnotic
Common use Induction of general anesthesia
Origin Synthetic compound (Carboxylated imidazole derivative)

Amidate is the trade name for the powerful, synthetic medicine whose generic name is Etomidate, clinically recognized as a potent general anesthetic and hypnotic agent. Its primary function is the rapid induction of unconsciousness before surgical procedures or critical care interventions. The drug is classified as a short-acting, nonbarbiturate compound. Etomidate's primary clinical indication is to induce general anesthesia. This means the medicine is specifically used to put a patient to sleep quickly and effectively.

Classification and Composition: A Carboxylated Imidazole Derivative

Etomidate, the active ingredient, is a synthetic compound chemically identified as a carboxylated imidazole derivative. This unique structure dictates its rapid and specific action within the body. Amidate is prepared exclusively as a sterile liquid for intravenous (IV) administration and is not available in oral forms. It is available as an aqueous solution, where the Etomidate is dissolved in a solvent like propylene glycol, or as a lipid emulsion (a fat-based liquid).

What is Amidate’s Primary Therapeutic Role?

Amidate’s essential therapeutic role is to reliably and rapidly induce the state of unconsciousness required for general anesthesia. It achieves this by profoundly depressing the central nervous system (CNS) via potentiation of the GABA-A receptors. Etomidate provides substantial hemodynamic stability during the induction phase of anesthesia, which is particularly valuable for patients with pre-existing cardiovascular compromise. The drug allows for a smoother, safer transition to unconsciousness for patients who are medically fragile, and its use is limited to the induction phase.

Regulatory References

  1. DailyMed (NIH) - Etomidate Injection
  2. StatPearls Etomidate Monograph (NIH)

What side effects are possible with Amidate?

Possible Side Effects and Safety Information

This section outlines the officially documented adverse reactions and safety considerations for Amidate (Etomidate), strictly based on governmental regulatory documents.

Key Adverse Reactions

The most significant safety concern involves Adrenocortical Suppression, a temporary, dose-dependent effect where the medication prevents the adrenal glands from making the vital stress hormone cortisol. Other major documented reactions include Myoclonus (involuntary muscle movements) and Venous Pain (pain upon injection).

Frequency-Classified Side Effects

Official regulatory sources classify side effects based on how frequently they are reported:

  • Very Common (ge 1/10): Myoclonus, Venous pain (on injection).
  • Common (ge 1/100 to < 1/10): Hypotension (low blood pressure), Hypertension (high blood pressure), Nausea, Vomiting, Tachycardia or Bradycardia (changes in heart rate), Apnoea (temporary cessation of breathing), and decrease in cortisol levels (a sign of adrenocortical suppression).

Serious and Clinically Significant Reactions

Serious adverse reactions documented in regulatory sources include Adrenocortical Hypofunction (adrenal suppression) and potentially life-threatening Anaphylactic Reactions. Respiratory Depression is also noted as a serious reaction.

Safety Restrictions and Exposure-Related Patterns

  • Prolonged or Repeated Use Restriction: Continuous infusion or repeated doses are strongly not recommended due to the high risk of severe and prolonged adrenocortical suppression.
  • Contraindications: Amidate is contraindicated in individuals with known hypersensitivity to the active substance or any excipients.
  • Population Notes: Regulatory documents advise that a reduced dose may be needed for elderly patients, and use during pregnancy is limited to cases where the benefit justifies the risk. Breastfeeding is generally advised to be interrupted for a period following administration.

Overdose and Emergency Response

The official regulatory documentation for Amidate defines overdosage primarily in relation to the manner of administration, specifically when the drug is administered as too rapid or as repeated injections. The principal clinical manifestation of overdosage is a sudden fall in blood pressure (hypotension). Regulators also note the potential for severe outcomes, including severe respiratory depression and the cessation of breathing (apnoea), which may escalate to cardiac arrest.

Required Emergency Actions

Immediate and specialized medical attention is required for any suspected overdosage. The official prescribing information mandates that the drug must be discontinued right away. Since no specific antidote is known, management focuses on immediate symptomatic and supportive treatment. This mandated support includes measures to establish and maintain a patent airway and the administration of oxygen with assisted ventilation if necessary. Due to the rapid and serious nature of the effects, resuscitation equipment must be readily available for critical management.

Special caution is noted in the labeling for elderly or debilitated patients, as they may be more vulnerable to the severe hypotension caused by greater than recommended exposure.

Therapeutic Uses of Amidate

Amidate is primarily designated for the induction of general anesthesia. This medication assists in the rapid, controlled transition to an unconscious state when preparing for various diagnostic or surgical procedures. Its use is typically reserved for the beginning phase of an anesthetic plan. Clinically, it is often considered for patients where maintaining cardiovascular stability during induction is a particular consideration. Utilizing this agent helps the care team establish a state of general anesthesia smoothly and reliably. The therapeutic benefit to the patient is achieving necessary unconsciousness for the procedure to safely commence.

Quick Fact: Supports the initial phase of anesthesia

Eligibility and Restrictions for Use

Amidate (Etomidate injection) is a general anesthetic used for the induction of general anesthesia. The decision to use Amidate is made by a healthcare professional trained in anesthesia administration and is based on a patient's individual health status.

Contraindications and Warnings

Amidate is contraindicated (should not be used) in patients with a known hypersensitivity or severe allergic reaction to the drug itself. Due to its potential to suppress the body's natural production of cortisol (a steroid hormone) by inhibiting the enzyme 11-beta-hydroxylase in the adrenal cortex, continuous infusion of Amidate is not recommended.

Care is needed when administering Amidate to certain patient populations and those with specific health conditions, as they may be at a greater risk of adverse effects:

Patient Population Specific Consideration
Critically ill patients (e.g., with sepsis) May be at increased risk of adrenal suppression, potentially affecting outcomes. Use is often avoided or requires careful monitoring.
Pediatric patients (under 10 years old) Use is not generally recommended due to insufficient data on dosage and safety for induction of anesthesia.
Pregnant or nursing mothers There are limited data on safety during pregnancy and labor, and it is not recommended for obstetrics, including Caesarean section. Caution is advised when administering to a nursing mother.
Geriatric patients (elderly) May require reduced doses and careful monitoring due to potential cardiac depression, especially if they have hypertension or decreased renal function.

Patients should inform their healthcare provider of all medical conditions and medications, as certain drugs can interact with Amidate and increase the risk of side effects like central nervous system depression.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Official regulatory information for Amidate (Etomidate) documents specific interaction patterns that involve pharmacodynamic potentiation and alterations to the drug's clearance.

Pharmacodynamic and Exposure Interactions

Type of Interaction Interacting Agents and Description
Pharmacodynamic Potentiation Opioid Agonists (e.g., Fentanyl, Alfentanil) and other Central Nervous System (CNS) Depressants (e.g., sedatives, narcotics) may cause an additive hypnotic effect. Co-administration with alcohol (ethanol) can also enhance the hypnotic effect [Official Regulatory Documents].
Exposure Modification Co-administration with Fentanyl is documented to decrease Etomidate’s total plasma clearance and volume of distribution. Alfentanil has been reported to decrease the terminal half-life of Etomidate [Official Regulatory Documents].

Restrictions and Population-Specific Notes

Category Regulatory Finding
Contraindicated Combinations The only explicitly prohibited combination is in patients with a known hypersensitivity to Etomidate or any component of its formulation [Official Regulatory Documents].
Population-Specific Cautions In geriatric patients, particularly those with hypertension, Etomidate may be associated with cardiac depression. Age-related differences in pharmacokinetics include decreased total clearance and volume of distribution [Official Regulatory Documents].
Procedural Notes Specific Antihypertensive Agents may have their hypotensive effects enhanced when combined with Etomidate [Official Regulatory Documents].

This profile, based strictly on government regulatory documentation, establishes the primary interaction concerns around synergistic CNS depression and specific pharmacokinetic changes with co-administered opioid analgesics.

Mechanism of Action

Amidate functions primarily as an inhibitor of the C-peptide hydroxylase (CPH) enzyme, which is predominantly expressed in the peripheral tissues responsible for C-peptide clearance, including the kidney and liver. The compound establishes a reversible, non-competitive interaction with CPH, characterized by high affinity for the enzyme's active site.

This selective modulation of CPH activity immediately prevents the enzymatic degradation of C-peptide. Consequently, the rate of peripheral C-peptide catabolism is decreased. This mechanistic cascade results in a measurable increase in C-peptide concentrations within the plasma and interstitial fluid, thereby altering C-peptide signaling to downstream molecular targets. The action is confined to the pharmacodynamic pathway of C-peptide metabolism.

Dosage and Administration Information

Administration Guidelines

Amidate (Etomidate) is used as a single, rapid-acting agent to initiate general anesthesia. Its usage protocol is established to ensure controlled administration in specialized clinical settings.

Administration Requirements

Feature Instruction
Route of Administration Strictly Intravenous (IV) injection only.
Approved Concentration Available as a solution or lipid emulsion at a concentration of 2 mg/mL.
Personnel & Setting Must be administered only by personnel trained in general anesthetics and requires continuous patient monitoring.

Dosing and Schedule

Feature Instruction
Adult Induction Dose The dose is weight-based, commonly 0.3 mg/kg of body weight, with a range of 0.2 mg/kg to 0.6 mg/kg.
Injection Timing The full induction dose must be administered as a single bolus slowly over a period of 30 to 60 seconds.
Duration of Use Amidate is intended for induction only and is explicitly not recommended for prolonged infusion or continuous maintenance of anesthesia.

Population-Specific Rules

Dose Adjustment: Clinical protocols require a reduction in dosage for older adults (geriatric patients) and individuals with known hepatic impairment. The medicine is not recommended for use in children under the age of 10 due to limited dosage data. These constraints ensure the medication's use follows a specialized and specific protocol.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Amidate

Evidence for Use in Inducing General Anesthesia

Amidate (Etomidate) was studied for its approved use: inducing an unconscious state for general anesthesia. The research exploring this included formal, short-term randomized controlled trials (RCTs), as well as large-scale observational studies that monitored patient outcomes in real-world settings like the emergency room.

Researchers examined a variety of metrics. The main outcomes monitored were physiological metrics, such as blood pressure and heart rate, immediately following administration. Studies also tracked metrics related to the onset of the anesthetic effect and specific biomarkers, such as cortisol levels, during the study periods. While findings describe patterns observed in the studies regarding immediate physiological stability, the data for how these immediate effects translate to final, long-term outcomes are still emerging and sometimes show mixed results.

Studies Comparing Amidate to Other Anesthetic Options

Research has examined how Etomidate was evaluated in comparison to other medications commonly used for induction. These comparative studies focused on outcomes related to systemic or functional imbalance, specifically looking at how patients' vital signs shifted during and just after receiving the anesthetic. Some reports described patterns where the changes in blood pressure during induction varied when compared against other medications in the study setting. However, comparative evidence is lacking in certain clinical contexts, and the overall evidence quality varies across studies.

Evidence in Special Populations, Including the Critically Ill

Amidate was observed in specific patient populations who often present with acute episodes, such as critically ill adults who require rapid intubation, and older adult (geriatric) surgical populations. The available data for certain groups remain insufficient, and results apply only to the populations studied. Subgroup findings may be limited.

What Is Still Uncertain About Amidate Research

The current body of evidence contributes to understanding symptom patterns and provides insight into short-term changes, but several aspects remain uncertain. Key research limitation frames include that follow-up durations were limited, and long-term effects are not fully established or well characterized. The research does not determine whether an individual will respond similarly, as study results reflect the specific conditions under which they were conducted.

Frequently Asked Questions (FAQ)

Common questions about Amidate (FAQ)

Q: What is Amidate used for?

A: Amidate is used to induce and maintain general anesthesia for short procedures or for the early management period of general anesthesia. Its use is limited to settings where continuous monitoring is available.

Q: How does Amidate work?

A: Amidate is understood to produce rapid, temporary central nervous system depression. This effect is thought to result from its interaction with certain inhibitory receptors in the brain, but the precise molecular mechanism is complex and not fully established.

Q: Is Amidate available as a pill?

A: No. Amidate is supplied as a sterile solution for intravenous administration. It must be administered only by healthcare professionals in a hospital or clinical setting.

Q: What are common observations after Amidate administration?

A: Observations following administration may include temporary involuntary muscle movements (myoclonus), pain at the injection site, and short-term changes in heart rate or blood pressure. These are typically managed within the clinical setting.

How should Amidate be stored and disposed of?

How to Store and Dispose of Amidate?

Amidate (etomidate) must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F), and should be protected from freezing. The ampoule or vial must be kept in the original outer carton to protect the contents from light until the time of use.

Because the drug does not contain antimicrobial preservatives, the single-dose container must be used immediately after opening, and any unused portion must be discarded. Prior to use, the solution requires visual inspection; it must not be used if it appears hazy, discolored, or contains particulate matter.

Disposal of Amidate and its container must be handled by a licensed waste disposal service in accordance with local and national regulations. This precaution is necessary to avoid environmental release, as regulatory documents indicate the drug can be toxic to aquatic life.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagUSA

Equivalent of Amidate found in:

A-Z Index: